ICMJE DISCLOSURE FORM

Date:			10/1/2022		
Your Name:			BHR Wolffenbuttel		
Manuscript Title:			Type 2 diabetes - Kan betere subtypering begeleiding en behandeling vergemakkelijken?		
Manuscript Number (if known):		(nown):	Click or tap here to enter text.		
content of your manuscript. "Rela affected by the content of the man			e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so.		
			es/interests should be defined broadly. For example, if your manuscript pertains to the u should declare all relationships with manufacturers of antihypertensive medication, even if in the manuscript.		
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.					
			l entities with whom you have this ship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initial planning	of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	⊠ No	one	Click the tab key to add additional rows.	
Time frame: past 36 months					
2	Grants or contracts from any entity (if not indicated in item #1 above).	Novo N		PI for the SURE-NL studsy	
3	Royalties or licenses	⊠ No	one		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	Novo Nordisk AS	European GLP1 advisory board
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Springer HealthCare Mednet Health Investment	EASD Highlights 2021 Coordinator / organiser for Post-Graduate Educations and Webinars
6	Payment for expert testimony	None ■	
7	Support for attending meetings and/or travel	□ None EASD European Assoc Study Diabetes	Annual meeting 2022, invited speaker & member post-graduate education committee
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	Novo Nordisk AS (see also item 4) Ancora Health Nuevo Care	European GLP1 advisory board Scientific advisory board Scientific advice and training
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
11	Stock or stock options	None ■				
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None				
13	Other financial or non-financial interests	Ournal of Diabetes Current Topics in Diabetes	Member Editorial Board Member Editorial Board			
Please place an "X" next to the following statement to indicate your agreement:						
\boxtimes	I certify that I have answered every question and have not altered the wording of any of the questions on this form.					